FrancophonIA/ELRC3.0 huggingface dataset:
English: VEGF-A acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.
Croatian: VEGF-A djeluje putem dviju receptorskih tirozin kinaza, VEGFR-1 i VEGFR-2, koje se nalaze na površini endotelnih stanica.
English: Please also read the package leaflets for the other medicines (‘chemotherapy') that are part of your treatment, to see if they are suitable for you.
Croatian: Pročitajte i Uputu o lijeku drugih lijekova (‘kemoterapije') koji čine dio Vašega liječenja kako biste vidjeli jesu li prikladni za Vas.
English: No studies have been conducted to assess the impact of ZALTRAP on milk production, its presence in breast milk or its effects on the breast-fed child.
Croatian: Nisu provedena ispitivanja kojima bi se ocijenio učinak lijeka ZALTRAP na stvaranje majčinog mlijeka, njegova prisutnost u majčinu mlijeku ni njegovi učinci na dojenče.
English: Filters made of polyvinylidene fluoride (PVDF) or nylon must not be used.
Croatian: Ne smiju se primjenjivati filtri načinjeni od polivinilidenfluorida (PVDF) ili najlona.
English: The treatment cycles on both arms were repeated every 2 weeks.
Croatian: Ciklusi liječenja su u obje skupine ponavljani svaka 2 tjedna.
English: Signs may include dizziness especially when going from sitting to standing.
Croatian: Znakovi mogu uključivati omaglicu, osobito pri ustajanju iz sjedećeg položaja.
English: If your white blood cells are low, your doctor may need to delay your treatment.
Croatian: Ako je broj bijelih krvnih stanica nizak, liječnik će možda morati odgoditi liječenje.
English: Aflibercept increased blood pressure in normotensive rodents.
Croatian: Aflibercept je povisio krvni tlak u normotenzivnih glodavaca.
English: Tests may include blood and urine tests, x-ray or other scanning techniques and/or other tests.
Croatian: Pretrage mogu uključivati pretrage krvi i mokraće, rendgensko snimanje ili druge tehnike oslikavanja i/ili druge testove.
English: You may have side effects that affect your sight, concentration or ability to react.
Croatian: Mogu se javiti nuspojave koje utječu na vid, koncentraciju ili sposobnost reagiranja.
English: Aflibercept is expected to degrade to small peptides and individual amino acids.
Croatian: Očekuje se razgradnja aflibercepta u male peptide i pojedinačne aminokiseline.
English: Your doctor may need to treat the allergic reaction or stop your treatment with ZALTRAP.
Croatian: Liječnik će možda morati liječiti alergijsku reakciju ili prekinuti liječenje lijekom ZALTRAP.
English: Neutropenia and neutropenic complications
Croatian: Neutropenija i neutropenijske komplikacije
English: • Hypertension that is not adequately controlled with anti-hypertensive therapy or occurrence of hypertensive crisis or hypertensive encephalopathy
Croatian: • hipertenzije koja se ne može adekvatno kontrolirati antihipertenzivima ili pojave hipertenzivne krize ili hipertenzivne encefalopatije
English: ZALTRAP should be used only if the potential benefit justifies the potential risk during pregnancy.
Croatian: ZALTRAP se smije primjenjivati samo ako moguća korist liječenja opravdava mogući rizik tijekom trudnoće.
English: • Based on the required dose for the patient, withdraw the necessary volume of ZALTRAP concentrate from the vial.
Croatian: • Na temelju doze koja je potrebna za bolesnika izvucite odgovarajući volumen ZALTRAP koncentrata iz bočice.
English: As with other large proteins, both free and bound aflibercept, are expected to be cleared, more slowly, by other biological mechanisms, such as proteolytic catabolism.
Croatian: Kao i kod drugih velikih proteina, očekuje se sporiji klirens slobodnog i vezanog aflibercepta drugim bioloških mehanizmima, poput proteolitičkog katabolizma.
English: Women of childbearing potential and fertile males should use effective contraception during and up to a minimum of 6 months after the last dose of treatment.
Croatian: Žene reproduktivne dobi i plodni muškarci moraju koristiti učinkovitu kontracepciju tijekom liječenja i najmanje 6 mjeseci nakon posljednje doze liječenja.
English: The diagnosis of PRES is confirmed by brain Magnetic Resonance Imaging (MRI).
Croatian: Dijagnoza PRES-a potvrđuje se magnetskom rezonancijom (MR) mozga.
English: • PVC containing DEHP infusion bags or polyolefin infusion bags should be used.
Croatian: • Moraju se koristiti infuzijske vrećice od PVC-a s DEHP-om ili poliolefinske infuzijske vrećice.
English: OS and PFS by stratification factors were performed.
Croatian: Provedene su analize OS i PFS prema faktorima stratifikacije.
English: Race No effect of race was identified in the population analysis.
Croatian: U populacijskoj analizi nije primijećen utjecaj rase.
English: Infection (1)
Croatian: infekcija (1)
English: • Posterior reversible encephalopathy syndrome (PRES) (also known as reversible posterior leukoencephalopathy syndrome (RPLS))
Croatian: • sindroma posteriorne reverzibilne encefalopatije (PRES) (poznat i kao sindrom reverzibilne posteriorne leukoencefalopatije (RPLS))
English: Other medicines and ZALTRAP
Croatian: Drugi lijekovi i ZALTRAP
English: After dilution in the infusion bag
Croatian: Nakon razrjeđivanja u infuzijskoj vrećici
English: As angiogenesis is critical to foetal development, the inhibition of angiogenesis following administration of ZALTRAP may result in adverse effects on pregnancy.
Croatian: Budući da je angiogeneza ključna za razvoj ploda, inhibicija angiogeneze nakon primjene lijeka ZALTRAP može štetno utjecati na trudnoću.
English: Most findings were considered to be related to the pharmacological activity of aflibercept.
Croatian: Za većinu se nalaza smatralo da su povezani s farmakološkom aktivnošću aflibercepta.
English: Any unused concentrate should be discarded.
Croatian: Neupotrijebljeni koncentrat mora se baciti.
English: Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX44
Croatian: Farmakoterapijska skupina: Antineoplastici, ostali antineoplastici, ATK oznaka: L01XX44
English: Table 4 - Post-hoc analyses excluding adjuvant patients a,b
Croatian: Tablica 4 - Post-hoc analize u koje nisu bili uključeni adjuvantni bolesnicia,b
English: Inform your doctor about your dental treatment and tell your dentist that you are being treated with ZALTRAP.
Croatian: Obavijestite Vašeg liječnika o stomatološkom liječenju i recite Vašem stomatologu da se liječite lijekom ZALTRAP.
English: There is no relevant use of ZALTRAP in the paediatric population for the indication of metastatic colorectal cancer.
Croatian: Nema relevantne primjene lijeka ZALTRAP u pedijatrijskoj populaciji u indikaciji metastatskog kolorektalnog karcinoma.
English: The European Medicines Agency has waived the obligation to conduct studies with ZALTRAP in all subsets of the paediatric population in adenocarcinoma of the colon and rectum (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu provođenja ispitivanja lijeka ZALTRAP u svim podskupinama pedijatrijske populacije u adenokarcinomu kolona i rektuma (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: No dose adjustment is required for aflibercept (see sections 4.2, 4.8 and 5.2).
Croatian: Nije potrebno prilagođavati dozu aflibercepta (vidjeti dio 4.2, 4.8 i 5.2).
English: This is because ZALTRAP may increase the risk of bleeding.
Croatian: Naime, ZALTRAP može povećati rizik od krvarenja.
English: Practical information for handling and administration of ZALTRAP for doctors, nurses and pharmacists when using this medicine is provided with this leaflet.
Croatian: Praktične informacije za rukovanje i primjenu lijeka ZALTRAP za liječnike, medicinske sestre i ljekarnike uključene su u ovu uputu.
English: • blood clot in very small blood vessels (also called ‘thrombotic microangiopathy').
Croatian: • krvni ugrušak u vrlo malim krvnim žilama (poznato i kao ‘trombotička mikroangiopatija').
English: Stratified log-rank test p-value
Croatian: p-vrijednost stratificiranog log-rang testa
English: versus 12.2 % Grades 3-4), increased AST (57.5 % versus 50.2 % all grades; 3.1 % versus 1.7% Grades 3-4), stomatitis (50.1 % versus 32.9 % all grades; 12.8 % versus 4.6 % Grades 3-4), fatigue (47.8 % versus 39.0 % all grades; 12.6 % versus 7.8 % Grade 3-4), thrombocytopenia (47.4 % versus 33.8 % all grades; 3.3 % versus 1.7 % Grades 3-4), increased ALT (47.3 % versus 37.1 % all grades; 2.7 % versus 2.2 % Grades 3-4), decreased appetite (31.9 % versus 23.8 % all grades; 3.4 % versus 1.8 % Grade 3-4), weight loss (31.9 % versus 14.4 % all grades; 2.6 % versus 0.8 % Grades 3-4), dysphonia (25.4 % versus 3.3 % all grades; 0.5 % versus 0 Grades 3-4), headache (22.3 % versus 8.8 % all grades; 1.6 % versus 0.3 % Grades 3-4), asthenia (18.3 % versus 13.2 % all grades; 5.1% versus 3.0 % Grades 3-4), Palmar- Plantar Erythrodysaesthesia syndrome (11.0 % versus 4.3 % all grades; 2.8 % versus 0.5 % Grades 3-4), and skin hyperpigmentation (8.2 % versus 2.8 % all grades; 0 versus 0 Grades 3-4).
Croatian: naspram 72,4%; stupanj 3-4: 15,6% naspram 12,2%), povišene vrijednosti AST-a (svi stupnjevi: 57,5% naspram 50,2%; stupanj 3-4: 3,1% naspram 1,7%), stomatitis (svi stupnjevi: 50,1% naspram 32,9%; stupanj 3-4: 12,8% naspram 4,6%), umor (svi stupnjevi: 47,8% naspram 39,0%; stupanj 3-4: 12,6% naspram 7,8%), trombocitopenija (svi stupnjevi: 47,4% naspram 33,8%; stupanj 3-4: 3,3% naspram 1,7%), povišene vrijednosti ALT-a (svi stupnjevi: 47,3% naspram 37,1%; stupanj 3-4: 2,7% naspram 2,2%), smanjen tek (svi stupnjevi: 31,9% naspram 23,8%; stupanj 3-4: 3,4% naspram 1,8%), gubitak tjelesne težine (svi stupnjevi: 31,9% naspram 14,4%; stupanj 3-4: 2,6% naspram 0,8%), disfonija (svi stupnjevi: 25,4% naspram 3,3%; stupanj 3-4: 0,5% naspram 0), glavobolja (svi stupnjevi: 22,3% naspram 8,8%; stupanj 3-4: 1,6% naspram 0,3%), astenija (svi stupnjevi: 18,3% naspram 13,2%; stupanj 3-4: 5,1% naspram 3,0%), sindrom palmarno-plantarne eritrodizestezije (svi stupnjevi: 11,0% naspram 4,3%; stupanj 3-4: 2,8% naspram 0,5%) hiperpigmentacija kože (svi stupnjevi: 8,2% naspram 2,8%; stupanj 3-4: 0 naspram 0).
English: What ZALTRAP is and what it is used for
Croatian: Što je ZALTRAP i za što se koristi
English: Analysis for OS and PFS by ECOG PS was also performed.
Croatian: Provedena je i analiza za OS i PFS prema ECOG statusu.
English: ZALTRAP has no or negligible influence on the ability to drive and use machines.
Croatian: ZALTRAP ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: If blood pressure is not controlled, it may cause stroke, heart and kidney problems.
Croatian: Ako se krvni tlak ne kontrolira, može izazvati moždani udar te tegobe sa srcem i bubrezima.
English: ZALTRAP will be given to you by a doctor or a nurse that is experienced in the use of ‘chemotherapy'.
Croatian: ZALTRAP će Vam dati liječnik ili medicinska sestra s iskustvom u primjeni ‘kemoterapije'.
English: These differences do not affect exposure due to weight-based dosing and no dose modifications based on gender are required.
Croatian: Navedene razlike ne utječu na izloženost zbog doziranja utemeljenog na tjelesnoj težini, pa nije potrebno prilagođavati dozu na temelju spola.
English: Before initiating ZALTRAP, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.
Croatian: Prije početka primjene lijeka ZALTRAP potrebno je pažljivo razmotriti ovaj rizik u bolesnika s čimbenicima rizika kao što su hipertenzija ili aneurizma u anamnezi.
English: However, results from a repeat dose toxicity study suggest there is a potential for aflibercept to impair reproductive function and fertility.
Croatian: Međutim, rezultati ispitivanja toksičnosti ponovljenih doza ukazuju na to da bi aflibercept mogao poremetiti reproduktivnu funkciju i plodnost.
English: If you are uncertain contact your doctor.
Croatian: Ako niste sigurni, obratite se liječniku.
English: Store in a refrigerator (2C - 8C).
Croatian: Čuvati u hladnjaku (2ºC - 8ºC).
English: 19.8 (16.4 to 23.2)
Croatian: 19,8 (16,4 do 23,2)
English: Hypertension may exacerbate underlying cardiovascular disease.
Croatian: Hipertenzija može prouzročiti egzacerbaciju podležeće kardiovaskularne bolesti.
English: Caution should be exercised when handling ZALTRAP, taking into account the use of containment devices, personal protective equipment (e.g. gloves), and preparation procedures.
Croatian: Pri rukovanju lijekom ZALTRAP nužan je oprez, a u obzir treba uzeti uporabu proizvoda za zaštitu od zagađenja, osobne zaštitne opreme (npr. rukavice) te postupke pripreme.
English: Your doctor may need to treat you with other medicines and/or fluids given intravenously.
Croatian: Liječnik će Vas možda morati liječiti drugim lijekovima i/ili tekućinama koje se primjenjuju u venu.
English: • DEHP free PVC containing trioctyl-trimellitate (TOTM)
Croatian: • PVC-a bez DEHP-a koji sadrži trioktil-trimelitat (TOTM)
English: Hypersensitivity to aflibercept or to any of the excipients listed in section 6.1.
Croatian: Preosjetljivost na aflibercept ili neku od pomoćnih tvari navedenih u dijelu 6.1.
English: Patients were treated until disease progression or unacceptable toxicity.
Croatian: Bolesnici su liječeni do progresije bolesti ili do pojave neprihvatljive toksičnosti.
English: Patients with thromboembolic events of Grade 3 or lower need to be closely monitored.
Croatian: Treba pomno nadzirati bolesnike s tromboembolijskim događajima stupnja 3 ili nižeg.
English: • pain in the mouth or throat
Croatian: • bol u ustima ili grlu
English: Aflibercept binds to human VEGF-A (equilibrium dissociation constant KD of 0.5 pM for VEGF-A165 and 0.36 pM for VEGF-A121), to human PlGF (KD of 39 pM for PlGF-2), and to human VEGF-B (KD of 1.92 pM) to form a stable, inert complex which has no detectable biological activity.
Croatian: Aflibercept se veže za humani VEGF-A (konstanta ravnoteže disocijacije KD od 0,5 pM za VEGF-A165 i 0,36 pM za VEGF-A121), humani PlGF (KD od 39 pM za PlGF-2) i humani VEGF-B (KD od 1,92 pM) i tako stvara stabilan, inertan kompleks koji nema mjerljivu biološku aktivnost.
English: Diarrhoea and dehydration
Croatian: Proljev i dehidracija
English: Oxaliplatin-based regimens were administered in combination with bevacizumab in 373 patients (30.4 %).
Croatian: Protokoli na bazi oksaliplatina primijenjeni su u kombinaciji s bevacizumabom u 373 bolesnika (30,4%).
English: Vascular endothelial growth factor A and B (VEGF-A, VEGF-B), and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells.
Croatian: Vaskularni endotelni faktor rasta A i B (engl. vascular endothelial growth factor A and B, VEGF-A, VEGF-B) i placentarni faktor rasta (engl. placental growth factor, PlGF) članovi su VEGF obitelji angiogenih faktora koji mogu djelovati kao snažni mitogeni, kemotaktični i faktori vaskularne propusnosti za endotelne stanice.
English: • during treatment with ZALTRAP and
Croatian: • tijekom liječenja lijekom ZALTRAP i
English: Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Croatian: U svakoj skupini učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
English: You should take your temperature often during treatment with this medicine.
Croatian: Tijekom liječenja ovim lijekom morate često mjeriti tjelesnu temperaturu.
English: 3.9 (3.02 to 4.30)
Croatian: 3,9 (3,02 do 4,30)
English: Zaltrap may reduce the number of white cells in your blood and your doctor will monitor your white blood cell count and may give you additional medicines to increase it.
Croatian: ZALTRAP može smanjiti broj bijelih krvnih stanica pa će Vam liječnik kontrolirati broj bijelih krvnih stanica i možda dati dodatne lijekove za povećavanje njihovog broja.
English: Precautions to be taken before handling or administering the medicinal product For instructions on dilution of the medicinal product before administration, and on infusion sets for administration, see section 6.6.
Croatian: Mjere opreza koje treba poduzeti prije rukovanja lijekom ili primjene lijeka Za upute o razrjeđivanju lijeka prije primjene, kao i o setovima za infuziju za primjenu lijeka, vidjeti dio 6.6.
English: Figure 1 - Overall survival (months) - Kaplan-Meier curves by treatment group - ITT population
Croatian: Slika 1 - Ukupno preživljenje (mjeseci) - Kaplan-Meierove krivulje prema ispitivanoj skupini - ITT
English: Population pharmacokinetics analysis and inter study comparisons did not reveal any pharmacokinetic drug-drug interaction between aflibercept and the FOLFIRI regimen.
Croatian: Populacijska farmakokinetička analiza i usporedbe između ispitivanja nisu otkrile nikakve farmakokinetičke interakcije između aflibercepta i protokola FOLFIRI.
English: If the patient becomes pregnant while taking ZALTRAP, she should be informed of the potential hazard to the foetus.
Croatian: Ako bolesnica zatrudni dok uzima ZALTRAP, mora biti upoznata s mogućim rizicima za plod.
English: • you have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction and especially if you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders).
Croatian: • ako imate problema s usnom šupljinom ili zubima kao što su loše zdravlje zubi, bolest desni ili planirano vađenje zuba, a posebno ako ste prije bili liječeni bisfosfonatom (koji se koristi za liječenje ili prevenciju poremećaja kostiju).
English: Treatment will continue as long as your doctor thinks the treatment is of benefit to you, and the side effects are acceptable.
Croatian: Liječenje će trajati onoliko dugo koliko liječnik bude smatrao da je korisno i sve dok nuspojave budu prihvatljive.
English: There is no information on the safety of aflibercept given at doses exceeding 7 mg/kg every 2 weeks or 9 mg/kg every 3 weeks.
Croatian: Nema podataka o sigurnosti aflibercepta primijenjenog u dozama višima od 7 mg/kg svaka 2 tjedna ili
English: Leucopenia (2) Neutropenia (2)
Croatian: leukopenija (2) neutropenija (2)
English: • drop in the number of white blood cells (leucopenia)
Croatian: • pad broja bijelih krvnih stanica (leukopenija)
English: Free aflibercept is primarily cleared by binding to endogenous VEGF to form a stable, inactive complex.
Croatian: Klirens slobodnog aflibercepta odvija se prvenstveno vezanjem za endogeni VEGF, pri čemu nastaje stabilan i neaktivan kompleks.
English: Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15 % of the total molecular mass, resulting in a total molecular weight of 115 kDa.
Croatian: Aflibercept je dimerički glikoprotein proteinske molekularne težine 97 kilodaltona (kDa), a sadrži glikozilaciju koja čini dodatnih 15% ukupne molekularne mase, pa ukupna molekularna težina iznosi
English: Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medicinal products, and underlying disease.
Croatian: Osim toga, na primijećenu incidenciju pozitivnih nalaza testa na protutijela može utjecati nekoliko čimbenika, uključujući rukovanje uzorkom, vrijeme prikupljanja uzorka, istodobno primijenjene lijekove i osnovnu bolest.
English: Excessive activation of these receptors by VEGF-A can result in pathological neovascularisation and excessive vascular permeability.
Croatian: Ako VEGF-A previše aktivira te receptore, može doći do patološke neovaskularizacije i prekomjerne vaskularne propusnosti.
English: At doses greater than 2 mg/kg, free aflibercept clearance was approximately 1.0L/day with a terminal half-life of 6 days.
Croatian: Pri dozama većim od 2 mg/kg klirens slobodnog aflibercepta iznosio je približno 1,0 l na dan, uz poluvijek od 6 dana.
English: • liver problem with an increase in liver enzymes.
Croatian: • tegobe s jetrom uz povišene vrijednosti jetrenih enzima.
English: performance status 1.
Croatian: status bio 2.
English: Animal toxicology and pharmacology
Croatian: Toksikologija i farmakologija u životinja
English: Information about storage and the time to use ZALTRAP, after it has been diluted and is ready to use, is described in the ‘Practical information for healthcare professionals on preparation and handling of ZALTRAP 25 mg / ml concentrate for solution for infusion' at the end of this leaflet.
Croatian: Informacije o čuvanju lijeka i vremenu unutar kojega se ZALTRAP mora primijeniti nakon razrjeđivanja i pripreme za primjenu opisane su u ‘Praktičnim informacijama za zdravstvene radnike o pripremi i rukovanju ZALTRAP 25 mg/ml koncentratom za otopinu za infuziju' na kraju ove upute.
English: The concentrate solution must be clear and without particles.
Croatian: Koncentrat za otopinu mora biti bistar i ne smije sadržavati čestice.
English: Dehydration (1) Decreased appetite Weight loss
Croatian: dehidracija (1) smanjen tek gubitak tjelesne težine
English: There is no specific antidote to ZALTRAP overdose.
Croatian: Ne postoji specifičan protulijek za predoziranje lijekom ZALTRAP.
English: Careful monitoring is recommended in order to rapidly detect and treat signs and symptoms of diarrhoea and dehydration and to minimize potential risk (see section 4.8).
Croatian: Preporučuje se pažljivo praćenje kako bi se brzo mogli otkriti i liječiti znakovi i simptomi proljeva i dehidracije te kako bi se umanjio mogući rizik (vidjeti dio 4.8).
English: Distribution The volume of distribution of free aflibercept at steady-state is approximately 8 litres.
Croatian: Volumen distribucije slobodnog aflibercepta u stanju dinamičke ravnoteže iznosi približno 8 litara.
English: In the event of hypertension on aflibercept treatment, blood pressure should be controlled with appropriate anti-hypertensive therapy and blood pressure should be monitored regularly.
Croatian: U slučaju razvoja hipertenzije tijekom liječenja afliberceptom treba regulirati krvni tlak odgovarajućom antihipertenzivnom terapijom te redovito kontrolirati krvni tlak.
English: No dose adjustments of ZALTRAP is required in the elderly people.
Croatian: Nije potrebno prilagođavati dozu lijeka ZALTRAP u starijih osoba.
English: ZALTRAP is a hyperosmotic solution, which is not formulated for compatibility with the intraocular environment.
Croatian: ZALTRAP je hiperosmotska otopina čija formulacija nije kompatibilna s intraokularnim okruženjem.
English: Your doctor should check your blood pressure throughout your treatment.
Croatian: Liječnik Vam tijekom cjelokupnog liječenja mora kontrolirati krvni tlak.
English: • you have had a tooth removed or any form of surgery in the last 4 weeks, or you are going to have an operation or a dental or medical procedure, or you have a wound after surgery that has not healed.
Croatian: • ako ste izvadili zub ili bili podvrgnuti bilo kakvoj operaciji u posljednja 4 tjedna, ako planirate operaciju, zahvat na zubima ili neki drugi medicinski zahvat, ili ako nakon operacije imate ranu koja još nije zacijelila.
English: If hypertension cannot be adequately controlled, treatment with aflibercept should not be initiated.
Croatian: Ako hipertenziju nije moguće adekvatno regulirati, ne smije se započinjati liječenje afliberceptom.
English: From a microbiological point of view, the solution for infusion should be used immediately.
Croatian: S mikrobiološkog stajališta, otopina za infuziju se mora odmah primijeniti.
English: • you experience signs of a blood clot (see section 4).
Croatian: • ako primijetite znakove krvnog ugruška (vidjeti dio 4.).
English: Observed effects included decreases in maternal body weights, an increased number of foetal resorptions, and an increased incidence of external, visceral, and skeletal foetal malformations.
Croatian: Primijećeni učinci uključivali su smanjenje tjelesne težine majke, povećan broj resorpcija ploda te povećanu incidenciju vanjskih, visceralnih i koštanih malformacija fetusa.